HPN HOSPITALIZED PNEUMONIA APPLICATION
|
|
- Kristopher Cook
- 6 years ago
- Views:
Transcription
1 HPN HOSPITALIZED PNEUMONIA APPLICATION Investigational Use. Not available for Sale in the United States.
2 Content UNYVERO HPN HOSPITALIZED PNEUMONIA APPLICATION The Unyvero HPN Pneumonia Application combines adequate detection of pathogens and antibiotic resistances to aid diagnosing pneumonia. A single test handles one patient sample analyzing 39 DNA targets and delivers reliable results within 4 hours. This approach facilitates a confident treatment decision at an earlier stage in the cycle of care. Infections and Resistances Faster diagnostics for pneumonia Increasing Antibiotic Resitances IDEAL PNEUMONIA ASSAY UNYVERO HPN HOSPITALIZED PNEUMONIA APPLICATION A broad spectrum established technologies in a new format Unyvero WORKFLOW Unyvero System And Applications UNYVERO AT A GLANCe Investigational Use. Not available for Sale in the United States. 3
3 Infections and Resistances INFECTIOUS DISEASES MEDICAL AND ECONOMIC BURDEN Severe acute infections and growing antibiotic resistances are a major burden for today s health care systems infections are together the number 3 cause of death. Fighting such infections would benefit from faster and more comprehensive diagnostics. The diagnosis and treatment of infections as it is today is imprecise and fraught with problems. Results from sample cultures usually take 2 days or longer. Clinicians must almost always begin treatment before results are available. In addition, antibiotic resistances compound the difficulty of therapy selection. They have risen steadily in the last several decades also due to inadequate antibiotic treatment. Clinical studies have demonstrated that adequate initial antibiotic treatment for most severe acute infections significantly improves medical outcome. In addition, appropriate and early antibiotic selection will limit the risk of increasing antibiotic resistance in the population as a whole. 4 Investigational Use. Not available for Sale in the United States. 5
4 Treating pneumonia patients with the right antibiotics at the right time often makes the difference between life and death. Faster diagnostics for pneumonia MEDICAL NEED IN PNEUMONIA FASTER DIAGNOSTIC TOOLS Pneumonia is a severe, life-threatening high incidence acute infection of the lower respiratory tract (LRT), which results from various causes, most commonly bacteria or viruses. It is a fast progressing disease with mortality rates up to 30% and an average hospital stay of 11 to 14 days associated with high treatment costs. The American Thoracic Society/Infectious Diseases Society of America (ATS/IDSA) guidelines distinguish the following types of pneumonia: > Community-acquired Pneumonia (CAP) is acquired in the community without a history of medical intervention. Often caused by viruses, they usually follow a mild course, however 25% of CAP need hospitalization (hcap). > Hospital-acquired (or nosocomial) Pneumonia (HAP) is a pneumonia that occurs 48 hours or more after admission and did not appear to be incubating at the time of admission. > ventilator-associated Pneumonia (VAP) is a type of HAP that develops more than 48 to 72 hours after endotracheal intubation. > Healthcare-associated Pneumonia (HCAP) is defined as pneumonia that occurs in a nonhospitalized patient with extensive healthcare contact. Studies have demonstrated, that the medical outcome of hcap and scap including VAP would certainly benefit from faster diagnostics. 6 Investigational Use. Not available for Sale in the United States. 7
5 Increasing Antibiotic Resitances GLOBAL CHALLENGE ANTIBIOTIC RESISTANCE > Antibiotic resistant bacteria have become an everyday occurrence and problem in hospitals across the world. > misuse of antibiotics may cause patients to become colonized or infected with antibiotic resistant bacteria, such as methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococci (VRE) and highly-resistant Gram-negative bacilli. > The emergence, selection and spread of resistant bacteria is a threat to patient safety in hospitals because: - infections with antibiotic resistant bacteria result in increased morbidity, mortality, and length of hospital stay. - antibiotic resistance frequently leads to a delay in appropriate antibiotic therapy. - inappropriate or delayed antibiotic therapy in patients with severe infections is associated with worse patient outcomes and sometimes death. - patients who are hospitalized have a high probability of receiving an antibiotic and 50% of all antibiotic use in hospitals can be inappropriate. - misuse of antibiotics in hospitals is one of the main factors that drive the development of antibiotic resistance. 8 Investigational Use. Not available for Sale in the United States. 9
6 Pneumonia causing pathogens Pneumonia Treatment guidelines Pneumonia Assay Hcap/ hcap Hap Vap Bacteria Viruses Fungi Hap Hcap/ hcap Vap Staphylococcus aureus Streptococcus pneumoniae Chlamydophila pneumoniae Enterobacteriaceae Staphylococcus aureus Streptococcus pneumoniae Pseudomonas aeruginosa Enterobacteriaceae Staphylococcus aureus Streptococcus pneumoniae Pseudomonas aeruginosa Enterobacteriaceae e.g. Piperacillin Ceftazidime Cefepime e.g. Erythromycin Azithromycin Clarithromycin e.g. Azithromycin Clarithromycin Levofloxacin e.g. Clindamycin Augmentin Piperacillin-tazobactam 1. Coverage Detects 90% of infectious disease causing pathogens 2. Diversity Enables testing of clinically relevant, different native 3. Speed Delivers clinically relevant answers in time Klebsiella pneumoniae Klebsiella pneumoniae Klebsiella pneumoniae Ticarcillin-clavulanic acid Levofloxacin Erythromycin Ticarcillin-clavulanic acid and clinically most relevant sample types Escherichia coli Legionella pneumophila Escherichia coli Proteus spp. Enterobacter spp. Haemophilus influenzae Erythromycin Azithromycin Augmentin Moxifloxacin Cefuroxime Piperacillin-tazobactam Ampicillin-sulbactam Cefoxitin antibiotic resistances Moraxella catarrhalis Haemophilus influenzae Pneumocystis jirovecii Enterobacter spp. Serratia marcescens Legionella pneumophila Stenotrophomonas maltophilia Ciprofloxacin Cefepime Clindamycin Levofloxacin > 35 genetic markers sputum, Lavage (BAL), tracheal aspirate 4 5 h Mycoplasma pneumoniae Moraxella catarrhalis Haemophilus influenzae Acinetobacter baumannii Candida spp. > 15 genetic markers to be tested Staphylococcus aureus Streptococcus pneumoniae Chlamydophila pneumoniae Serratia marcescens Legionella pneumophila Moraxella catarrhalis Risk: Antibiotic resistance PreRequisites Pseudomonas aeruginosa Haemophilus influenza Enterobacteriaceae Stenotrophomonas maltophilia Escherichia coli Acinetobacter baumannii Klebsiella pneumoniae Pneumocystis jirovecii Proteus spp. Enterobacter spp. Mycoplasma pneumoniae Important genetic resistance markers > should work with various native samples > needs sample preparation with high DNA yield An ideal Pneumonia assay should cover 90 % have to be tested in an ideal Pneumonia assay > allows multiplex PCR of up to 100 analytes of pathogens causing hospitalized pneumonia > requires highly specific detection 10 Investigational Use. Not available for Sale in the United States. 13
7 UNYVERO HPN HOSPITALIZED PNEUMONIA APPLICATION PCR set-up PREREQUISITES FOR AN IDEAL SOLUTION UNYVERO HPN HOSPITALIZED PNEUMONIA APPLICATION DNA purification Multiplex PCR with array detection PNEUMONIA ASSAY: The unique Unyvero HPN HOSPITALIZED PNEUMONIA CARTRIDGE allows the detection of 39 analytes and integrates Unique solution tailored to clinical needs > COVERAGE > DNA purification, > PCR set-up, > multiplex endpoint PCR and, > amplicon detection by array hybridization. > Comprehensive, disease-oriented test panels run on an easy to operate platform, requiring neither the special infrastructure of a laboratory environment nor specially trained personnel. > DIVERSITY > SPEED Therefore, the closed Unyvero Cartridge is equipped with integrated reagent containers, a DNA purification column, eight PCR chambers and an according number of arrays. The cartridge is pre-filled with buffers for DNA cleanup, reagents and fluorescence-labeled primers for PCR amplification, respectively for array hybridization of the PCR product. > Translates a complex laboratory process into an easy to use format. The analytical process requires only addition of the unprocessed patient sample and enzymes for DNA amplification. > Generates complete diagnostic information in 4 5 hours, without any further operator interaction. 1. Unyvero T1 Sample Tube for preparation of the patient sample, pre-filled with specific lysis reagents. 2. Unyvero T1 Sample Tube Cap seals the Unyvero Sample Tube and contains proteinase K and an internal control gene for quality control. 3. Unyvero T1 Sample Transfer Tool is a pipetting aid for use with a 1 ml Luer-lock syringe. 4. Unyvero M1 Master Mix Tube with reagents for DNA amplification Investigational Use. Not available for Sale in the United States. 15
8 A broad spectrum COVERAGE CLINICALLY RELEVANT PATHOGENS AND ANTIBIOTIC RESISTANCES Group Gram-positive bacteria Enterobacteriaceae Non-fermenting bacteria Others / Fungi Pathogen Staphylococcus aureus Streptococcus pneumoniae Citrobacter freundii Escherichia coli Enterobacter cloacae complex Enterobacter aerogenes Proteus spp. Klebsiella pneumoniae Klebsiella oxytoca Klebsiella variicola Serratia marcescens Morganella morganii Moraxella catarrhalis Pseudomonas aeruginosa Acinetobacter baumannii complex Stenotrophomonas maltophilia Legionella pneumophila Pneumocystis jirovecii Haemophilus influenzae Mycoplasma pneumoniae In Pneumonia, the early detection of pathogens and antibiotic resistances is key to improving clinical outcome. The Unyvero System uniquely addresses the analysis of antibiotic resistance markers simultaneously with the pathogen detection. The Unyvero Hospitalized Pneumonia panel of microorganisms and resistance gene markers is designed based on feedback of clinical experts and international, as well as national treatment guidelines.* The panel is primarily designed to capture patients at risks for > pathogens causing severe, difficult to treat forms of pneumonia e.g. Pseudomonas aeruginosa, pathogens carrying antibiotic resistance and where patients may need isolation (Klebsiella spp., Acinetobacter spp.) > infections with multidrug-resistant bacteria, that might not be targeted by empiric treatment schemes. In addition, for the panel composition pathogen incidences have been taken into account, thus it includes those microorganisms showing an incidence of above 5%. The panel is completed by adding difficult to diagnose pathogens (e.g. Legionella pneumophila) with lower incidence, but with a rather high clinical impact. The Curetis Unyvero HOSPITALIZED Pneumonia panel targets the following antimicrobial classes by analyzing 19 genetic markers > ß-lactam-resistance > Macrolide-resistance > Fluoroquinolone resistance > resistance as clinically most relevant in pneumonia causing pathogens. Gene ermb meca mecc tem shv ctx-m kpc imp ndm oxa-23 oxa-24 / 40 oxa-48 oxa-58 vim sul1 gyra83 gyra87 resistance against Macrolide/Lincosamide Oxacillin Oxacillin Penicillin Penicillin 3rd generation Cephalosporins Sulfonamide Fluoroquinolone Fluoroquinolone * CDC: Prevention of Healthcare-Associated Pneumonia, Management of mdr Organisms in Healthcare Settings, American Thoracic Society: HAP, VAP, HCAP II Guideline, CAP Guideline Paul-Ehrlich-Gesellschaf: CAP-Leitlinie: Nosocomial pneumonia: prevention, diagnosis, treatment, European Respiratory Society: Lower Respiratory Tract Infections, British Society of Antimicrobial Chemotherapy: HAP Guideline, Canadian GuidelineCommittee: VAP Diagnosis and Treatment. 16 Investigational Use. Not available for Sale in the United States. 17
9 established technologies in a new format DIVERSITY HIGHLY SPECIFIC MULTIPLEX PCR and FAST ARRAY-BASED DETECTION Pathogen DNA Specific Amplification Specific Target Hybridization Detection and Specific Control Sample Types Sample Quality One of Curetis core competencies is the design of reliable > sputum > lavage (BAL) > tracheal aspirate > liquid > viscous > contaminated with - cells - blood bio-assays in self-contained cartridges for enabling sensitive multiplex testing. The required multiplex grade is achieved by combining the unmatched sample preparation and PCR technology with a proprietary detection array. Endpoint-PCR can deliver higher multiplex grades than most other amplification methods and in that respect holds clear advantages over e.g. real-time PCR. vim Curetis` proprietary and universal sample preparation technology prepares DNA from any native clinical sample type without losing time for preculturing. Curetis` technology efficiently extracts DNA from different microorganisms (Gram-positive and Gram-negative bacteria, fungi and other intracellular organisms) even in complex samples like highly viscous sputa or in samples contaminated with blood. Because of its universal applicability the Curetis technology can use a single protocol for sample preparation for many different sample types in any clinical application. The array has been optimized for hybridization times of a few minutes compared to standard arrays. To enhance specificity, the dissociation kinetics of the array hybridization are automatically assessed. In addition with each patient sample, an artificial gene is simultaneously processed as internal process control. The control verifies all PCR steps, as well as the array hybridization. Pneumocystis jirovecii 18 Investigational Use. Not available for Sale in the United States. 19
10 Unyvero Workflow Unyvero Workflow SPEED UNYVERO SOLUTION`S SIMPLIFIED WORKFLOW The intuitive simple workflow is consistent across all clinical applications and sample types, thus drastically reducing invalid tests due to operator errors. Step 1 Transfer of samples and lysis Step 2 Assembling the Unyvero Cartridge Step 3 Scanning and inserting the Unyvero Cartridge Step 4 Four to five-hour analysis process Working time ~ 60 seconds: ~ 30 seconds: ~ 20 seconds: It takes just a few minutes for subsequent analysis of the results: 1. The patient sample is transferred to the Unyvero Sample Tube, then sealed in with the Unyvero Sample Tube Cap and lysed for 30 minutes in the Unyvero Lysator. 2. After 30 minutes, the Unyvero Sample Tube can be removed from the Lysator and inserted together with the Unyvero Master Mix Tube into the corresponding Unyvero Cartridge. 3. The cartridge is now scanned and inserted into the Unyvero Analyzer. Up to two cartridges per analyzer can be analyzed simultaneously. 4. The Unyvero analysis now runs for four to five hours. The results are then displayed on the screen or can be exported as a PDF. 20 Investigational Use. Not available for Sale in the United States. 21
11 Unyvero System And Applications UNYVERO SYSTEM UNIVERSAL PLATFORM FEATURING MANY DIFFERENT APPLICATIONS The Unyvero Solution features a Unyvero L4 Lysator Unyvero C8 Cockpit Unyvero A50 Analyzer»sample to answers«approach and consists of: > the Unyvero L4 Lysator for sample lysis > the application specific Unyvero Cartridge > the Unyvero A50 Analyzer handling the Unyvero Cartridge > the Unyvero C8 Cockpit for intuitive user interaction > and the optional Unyvero Server Software for integration into the hospital`s information systems Unyvero Application Cartridges The Unyvero System translates a complex laboratory and the Master Mix are inserted into the cartridge, the process into an easy-to-use format. The analytical cartridge is loaded into the analyzer and processed fully process requires merely the addition of the unprocessed automatically. The Unyvero System generates complete patient sample and enzymes for DNA amplification. diagnostic information in 4 5 hours, without any further All other reagents are preloaded into a self-contained, operator interaction. contamination safe cartridge. After the patient sample 22 Investigational Use. Not available for Sale in the United States. 23
12 At A Glance UNyvero at a glance The Unyvero Solution > detects broad panels of pathogens and antibiotic resistances from a single sample in one run > enables testing of many clinically relevant native samples > delivers clinically relevant information in 4 5 hours, to aid an informed therapy decision as early as possible > enables point of need testing > provides high productivity through - minimizing operator time to a few minutes with full walk-away automation based on a simple and consistent workflow for any clinical application - low implementation requirements and low total cost of ownership, as no staff with molecular biology skills nor special infrastructure is needed - configurations that meet individual customer needs, satisfying any throughput demands - optimizing the routine hospital workflow by sophisticated information management 24 Investigational Use. Not available for Sale in the United States. 25
13 Curetis GmbH Max-Eyth-Str Holzgerlingen Germany Tel.:+49 (0) Rev5.0 Curetis GmbH Investigational Use. Not available for Sale in the United States.
Concise Antibiogram Toolkit Background
Background This toolkit is designed to guide nursing homes in creating their own antibiograms, an important tool for guiding empiric antimicrobial therapy. Information about antibiograms and instructions
More informationRapid Diagnosis by Multiplex PCR Technology at Patients with Acute Respiratory Infections
American Association for Science and Technology AASCIT Communications Volume 1, Issue 3 October 20, 2014 online Rapid Diagnosis by Multiplex PCR Technology at Patients with Acute Respiratory Infections
More informationManagement of Hospital-acquired Pneumonia
Management of Hospital-acquired Pneumonia Adel Alothman, MB, FRCPC, FACP Asst. Professor, COM, KSAU-HS Head, Infectious Diseases, Department of Medicine King Abdulaziz Medical City Riyadh Saudi Arabia
More information2015 Antibiotic Susceptibility Report
Citrobacter freundii Enterobacter aerogenes Enterobacter cloacae Escherichia coli Haemophilus influenzenza Klebsiella oxytoca Klebsiella pneumoniae Proteus mirabilis Pseudomonas aeruginosa Serratia marcescens
More information2012 ANTIBIOGRAM. Central Zone Former DTHR Sites. Department of Pathology and Laboratory Medicine
2012 ANTIBIOGRAM Central Zone Former DTHR Sites Department of Pathology and Laboratory Medicine Medically Relevant Pathogens Based on Gram Morphology Gram-negative Bacilli Lactose Fermenters Non-lactose
More information2016 Antibiotic Susceptibility Report
Fairview Northland Medical Center and Elk River, Milaca, Princeton and Zimmerman Clinics 2016 Antibiotic Susceptibility Report GRAM-NEGATIVE ORGANISMS 2016 Gram-Negative Non-Urine The number of isolates
More informationNational Clinical Guideline Centre Pneumonia Diagnosis and management of community- and hospital-acquired pneumonia in adults
National Clinical Guideline Centre Antibiotic classifications Pneumonia Diagnosis and management of community- and hospital-acquired pneumonia in adults Clinical guideline 191 Appendix N 3 December 2014
More informationMICRONAUT MICRONAUT-S Detection of Resistance Mechanisms. Innovation with Integrity BMD MIC
MICRONAUT Detection of Resistance Mechanisms Innovation with Integrity BMD MIC Automated and Customized Susceptibility Testing For detection of resistance mechanisms and specific resistances of clinical
More informationAntimicrobial Susceptibility Testing: Advanced Course
Antimicrobial Susceptibility Testing: Advanced Course Cascade Reporting Cascade Reporting I. Selecting Antimicrobial Agents for Testing and Reporting Selection of the most appropriate antimicrobials to
More informationSHC Clinical Pathway: HAP/VAP Flowchart
SHC Clinical Pathway: Hospital-Acquired and Ventilator-Associated Pneumonia SHC Clinical Pathway: HAP/VAP Flowchart v.08-29-2017 Diagnosis Hospitalization (HAP) Pneumonia develops 48 hours following: Endotracheal
More informationAppropriate antimicrobial therapy in HAP: What does this mean?
Appropriate antimicrobial therapy in HAP: What does this mean? Jaehee Lee, M.D. Kyungpook National University Hospital, Korea KNUH since 1907 Presentation outline Empiric antimicrobial choice: right spectrum,
More informationTHE NAC CHALLENGE PANEL OF ISOLATES FOR VERIFICATION OF ANTIBIOTIC SUSCEPTIBILITY TESTING METHODS
THE NAC CHALLENGE PANEL OF ISOLATES FOR VERIFICATION OF ANTIBIOTIC SUSCEPTIBILITY TESTING METHODS Stefanie Desmet University Hospitals Leuven Laboratory medicine microbiology stefanie.desmet@uzleuven.be
More informationNew Opportunities for Microbiology Labs to Add Value to Antimicrobial Stewardship Programs
New Opportunities for Microbiology Labs to Add Value to Antimicrobial Stewardship Programs Patrick R. Murray, PhD Senior Director, WW Scientific Affairs 2017 BD. BD, the BD Logo and all other trademarks
More informationGuidelines for Laboratory Verification of Performance of the FilmArray BCID System
Guidelines for Laboratory Verification of Performance of the FilmArray BCID System Purpose The Clinical Laboratory Improvement Amendments (CLIA), passed in 1988, establishes quality standards for all laboratory
More informationTable 1. Commonly encountered or important organisms and their usual antimicrobial susceptibilities.
Table 1. Commonly encountered or important organisms and their usual antimicrobial susceptibilities. Gram-positive cocci: Staphylococcus aureus: *Resistance to penicillin is almost universal. Resistance
More informationBACTERIAL SUSCEPTIBILITY REPORT: 2016 (January 2016 December 2016)
BACTERIAL SUSCEPTIBILITY REPORT: 2016 (January 2016 December 2016) VA Palo Alto Health Care System April 14, 2017 Trisha Nakasone, PharmD, Pharmacy Service Russell Ryono, PharmD, Public Health Surveillance
More informationRCH antibiotic susceptibility data
RCH antibiotic susceptibility data The following represent RCH antibiotic susceptibility data from 2008. This data is used to inform antibiotic guidelines used at RCH. The data includes all microbiological
More information4 th and 5 th generation cephalosporins. Naderi HR Associate professor of Infectious Diseases
4 th and 5 th generation cephalosporins Naderi HR Associate professor of Infectious Diseases Classification Forth generation: Cefclidine, cefepime (Maxipime),cefluprenam, cefoselis,cefozopran, cefpirome
More informationAntimicrobial susceptibility
Antimicrobial susceptibility PATTERNS Microbiology Department Canterbury ealth Laboratories and Clinical Pharmacology Department Canterbury District ealth Board March 2011 Contents Preface... Page 1 ANTIMICROBIAL
More information2015 Antibiogram. Red Deer Regional Hospital. Central Zone. Alberta Health Services
2015 Antibiogram Red Deer Regional Hospital Central Zone Alberta Health Services Introduction. This antibiogram is a cumulative report of the antimicrobial susceptibility rates of common microbial pathogens
More information2015 Antimicrobial Susceptibility Report
Gram negative Sepsis Outcome Programme (GNSOP) 2015 Antimicrobial Susceptibility Report Prepared by A/Professor Thomas Gottlieb Concord Hospital Sydney Jan Bell The University of Adelaide Adelaide On behalf
More information2009 ANTIBIOGRAM. University of Alberta Hospital and the Stollery Childrens Hospital
2009 ANTIBIOGRAM University of Alberta Hospital and the Stollery Childrens Hospital Division of Medical Microbiology Department of Laboratory Medicine and Pathology 2 Table of Contents Page Introduction.....
More information2017 Antibiogram. Central Zone. Alberta Health Services. including. Red Deer Regional Hospital. St. Mary s Hospital, Camrose
2017 Antibiogram Central Zone Alberta Health Services including Red Deer Regional Hospital St. Mary s Hospital, Camrose Introduction This antibiogram is a cumulative report of the antimicrobial susceptibility
More information2010 ANTIBIOGRAM. University of Alberta Hospital and the Stollery Children s Hospital
2010 ANTIBIOGRAM University of Alberta Hospital and the Stollery Children s Hospital Medical Microbiology Department of Laboratory Medicine and Pathology Table of Contents Page Introduction..... 2 Antibiogram
More informationC&W Three-Year Cumulative Antibiogram January 2013 December 2015
C&W Three-Year Cumulative Antibiogram January 213 December 215 Division of Microbiology, Virology & Infection Control Department of Pathology & Laboratory Medicine Contents Comments and Limitations...
More informationAntibiotic. Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting
Antibiotic Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting Any substance of natural, synthetic or semisynthetic origin which at low concentrations kills or inhibits the growth of bacteria
More information2016 Antibiogram. Central Zone. Alberta Health Services. including. Red Deer Regional Hospital. St. Mary s Hospital, Camrose
2016 Antibiogram Central Zone Alberta Health Services including Red Deer Regional Hospital St. Mary s Hospital, Camrose Introduction This antibiogram is a cumulative report of the antimicrobial susceptibility
More informationCONTAGIOUS COMMENTS Department of Epidemiology
VOLUME XXIII NUMBER 1 July 2008 CONTAGIOUS COMMENTS Department of Epidemiology Bugs and Drugs Elaine Dowell, SM (ASCP), Marti Roe SM (ASCP), Ann-Christine Nyquist MD, MSPH Are the bugs winning? The 2007
More informationAberdeen Hospital. Antibiotic Susceptibility Patterns For Commonly Isolated Organisms For 2015
Aberdeen Hospital Antibiotic Susceptibility Patterns For Commonly Isolated s For 2015 Services Laboratory Microbiology Department Aberdeen Hospital Nova Scotia Health Authority 835 East River Road New
More informationCONTAGIOUS COMMENTS Department of Epidemiology
VOLUME XXIX NUMBER 3 November 2014 CONTAGIOUS COMMENTS Department of Epidemiology Bugs and Drugs Elaine Dowell SM MLS (ASCP), Marti Roe SM MLS (ASCP), Sarah Parker MD, Jason Child PharmD, and Samuel R.
More informationMercy Medical Center Des Moines, Iowa Department of Pathology. Microbiology Department Antibiotic Susceptibility January December 2016
Mercy Medical Center Des Moines, Iowa Department of Pathology Microbiology Department Antibiotic Susceptibility January December 2016 These statistics are intended solely as a GUIDE to choosing appropriate
More information4/3/2017 CLINICAL PEARLS: UPDATES IN THE MANAGEMENT OF NOSOCOMIAL PNEUMONIA DISCLOSURE LEARNING OBJECTIVES
CLINICAL PEARLS: UPDATES IN THE MANAGEMENT OF NOSOCOMIAL PNEUMONIA BILLIE BARTEL, PHARMD, BCCCP APRIL 7 TH, 2017 DISCLOSURE I have had no financial relationship over the past 12 months with any commercial
More informationEuropean Committee on Antimicrobial Susceptibility Testing
European Committee on Antimicrobial Susceptibility Testing Routine and extended internal quality control as recommended by EUCAST Version 5.0, valid from 015-01-09 This document should be cited as "The
More informationINFECTIOUS DISEASES DIAGNOSTIC LABORATORY NEWSLETTER
INFECTIOUS DISEASES DIAGNOSTIC LABORATORY NEWSLETTER University of Minnesota Health University of Minnesota Medical Center University of Minnesota Masonic Children s Hospital May 2017 Printed herein are
More informationEuropean Committee on Antimicrobial Susceptibility Testing
European Committee on Antimicrobial Susceptibility Testing Routine and extended internal quality control for MIC determination and disk diffusion as recommended by EUCAST Version 8.0, valid from 018-01-01
More informationPDF hosted at the Radboud Repository of the Radboud University Nijmegen
PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/26062
More informationAntibiotic Resistance. Antibiotic Resistance: A Growing Concern. Antibiotic resistance is not new 3/21/2011
Antibiotic Resistance Antibiotic Resistance: A Growing Concern Judy Ptak RN MSN Infection Prevention Practitioner Dartmouth-Hitchcock Medical Center Lebanon, NH Occurs when a microorganism fails to respond
More information5/4/2018. Multidrug Resistant Organisms (MDROs) Objectives. Outline. Define a multi-drug resistant organism (MDRO)
Multidrug Resistant Organisms (MDROs) Kasturi Shrestha, M.D. 05/11/2018 Objectives Define a multi-drug resistant organism (MDRO) Identify most challenging MDROs in healthcare Identify reasons for health
More informationMechanism of antibiotic resistance
Mechanism of antibiotic resistance Dr.Siriwoot Sookkhee Ph.D (Biopharmaceutics) Department of Microbiology Faculty of Medicine, Chiang Mai University Antibiotic resistance Cross-resistance : resistance
More information9/30/2016. Dr. Janell Mayer, Pharm.D., CGP, BCPS Dr. Lindsey Votaw, Pharm.D., CGP, BCPS
Dr. Janell Mayer, Pharm.D., CGP, BCPS Dr. Lindsey Votaw, Pharm.D., CGP, BCPS 1 2 Untoward Effects of Antibiotics Antibiotic resistance Adverse drug events (ADEs) Hypersensitivity/allergy Drug side effects
More informationmicrobiology testing services
microbiology testing services You already know Spectra Laboratories for a wide array of dialysis-related testing services. Now get to know us for your microbiology needs. As the leading provider of renal-specific
More informationWhat is pneumonia? Infection of the lung parenchyma Causative agents include bacteria, viruses, fungi, protozoa.
Pneumonia What is pneumonia? Infection of the lung parenchyma Causative agents include bacteria, viruses, fungi, protozoa www.netmedicine.com/xray/xr.htm Definition acute infectious disease, etiology usually
More informationChallenges Emerging resistance Fewer new drugs MRSA and other resistant pathogens are major problems
Micro 301 Antimicrobial Drugs 11/7/12 Significance of antimicrobial drugs Challenges Emerging resistance Fewer new drugs MRSA and other resistant pathogens are major problems Definitions Antibiotic Selective
More informationGENERAL NOTES: 2016 site of infection type of organism location of the patient
GENERAL NOTES: This is a summary of the antibiotic sensitivity profile of clinical isolates recovered at AIIMS Bhopal Hospital during the year 2016. However, for organisms in which < 30 isolates were recovered
More informationBurton's Microbiology for the Health Sciences. Chapter 9. Controlling Microbial Growth in Vivo Using Antimicrobial Agents
Burton's Microbiology for the Health Sciences Chapter 9. Controlling Microbial Growth in Vivo Using Antimicrobial Agents Chapter 9 Outline Introduction Characteristics of an Ideal Antimicrobial Agent How
More informationIntrinsic, implied and default resistance
Appendix A Intrinsic, implied and default resistance Magiorakos et al. [1] and CLSI [2] are our primary sources of information on intrinsic resistance. Sanford et al. [3] and Gilbert et al. [4] have been
More information1/30/ Division of Disease Control and Health Protection. Division of Disease Control and Health Protection
Surveillance, Outbreaks, and Reportable Diseases, Oh My! Assisted Living Facility, Nursing Home and Surveyor Infection Prevention Training February 2015 A.C. Burke, MA, CIC Health Care-Associated Infection
More informationAntimicrobial Stewardship:
Antimicrobial Stewardship: Inpatient and Outpatient Elements Angela Perhac, PharmD afperhac@carilionclinic.org Disclosure I have no relevant finances to disclose. Objectives Review the core elements of
More informationAntimicrobial Cycling. Donald E Low University of Toronto
Antimicrobial Cycling Donald E Low University of Toronto Bad Bugs, No Drugs 1 The Antimicrobial Availability Task Force of the IDSA 1 identified as particularly problematic pathogens A. baumannii and
More informationInfection Control of Emerging Diseases
2016 EPS Training Event Martin E. Evans, MD Director, VHA MDRO Program National Infectious Diseases Service Lexington, KY & Cincinnati, OH Infection Control of Emerging Diseases 2016 EPS Training Event
More informationAntimicrobial Susceptibility Patterns
Antimicrobial Susceptibility Patterns KNH SURGERY Department Masika M.M. Department of Medical Microbiology, UoN Medicines & Therapeutics Committee, KNH Outline Methodology Overall KNH data Surgery department
More informationDrive More Efficient Clinical Action by Streamlining the Interpretation of Test Results
White Paper: Templated Report Comments Drive More Efficient Clinical Action by Streamlining the Interpretation of Test Results Background The availability of rapid, multiplexed technologies for the comprehensive
More informationNon-Susceptibility of Bacterial Pathogens Causing Hospital-Onset Pneumonia UK and Ireland,
Non-Susceptibility of Bacterial Pathogens Causing Hospital-Onset Pneumonia UK and Ireland, 2008-2016 Alicia Russell Federation of Infection Societies conference 14 th November 2018 alisia_russell BSAC
More informationMultidrug-Resistant Organisms: How Do We Define them? How do We Stop Them?
Multidrug-Resistant Organisms: How Do We Define them? How do We Stop Them? Roberta B. Carey, PhD Centers for Disease Control and Prevention Division of Healthcare Quality Promotion Why worry? MDROs Clinical
More informationApproach to pediatric Antibiotics
Approach to pediatric Antibiotics Gassem Gohal FAAP FRCPC Assistant professor of Pediatrics objectives To be familiar with common pediatric antibiotics o Classification o Action o Adverse effect To discus
More informationHelp with moving disc diffusion methods from BSAC to EUCAST. Media BSAC EUCAST
Help with moving disc diffusion methods from BSAC to EUCAST This document sets out the main differences between the BSAC and EUCAST disc diffusion methods with specific emphasis on preparation prior to
More informationRAPID IDENTIFICATION OF RESISTANCE MECHANISMS
RAPID IDENTIFICATION OF RESISTANCE MECHANISMS Christine C. Ginocchio, PhD, MT (ASCP) Professor of Medicine, Hofstra North Shore-LIJ School of Medicine, NY VP, Global Microbiology Affairs, biomerieux VP,
More informationESBL Producers An Increasing Problem: An Overview Of An Underrated Threat
ESBL Producers An Increasing Problem: An Overview Of An Underrated Threat Hicham Ezzat Professor of Microbiology and Immunology Cairo University Introduction 1 Since the 1980s there have been dramatic
More informationAntibiotic Stewardship Program (ASP) CHRISTUS SETX
Antibiotic Stewardship Program (ASP) CHRISTUS SETX Program Goals I. Judicious use of antibiotics Decrease use of broad spectrum antibiotics and deescalate use based on clinical symptoms Therapeutic duplication:
More informationINCIDENCE OF BACTERIAL COLONISATION IN HOSPITALISED PATIENTS WITH DRUG-RESISTANT TUBERCULOSIS
INCIDENCE OF BACTERIAL COLONISATION IN HOSPITALISED PATIENTS WITH DRUG-RESISTANT TUBERCULOSIS 1 Research Associate, Drug Utilisation Research Unit, Nelson Mandela University 2 Human Sciences Research Council,
More informationInt.J.Curr.Microbiol.App.Sci (2017) 6(3):
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 6 Number 3 (2017) pp. 891-895 Journal homepage: http://www.ijcmas.com Original Research Article https://doi.org/10.20546/ijcmas.2017.603.104
More informationUnderstanding the Hospital Antibiogram
Understanding the Hospital Antibiogram Sharon Erdman, PharmD Clinical Professor Purdue University College of Pharmacy Infectious Diseases Clinical Pharmacist Eskenazi Health 5 Understanding the Hospital
More informationSuggestions for appropriate agents to include in routine antimicrobial susceptibility testing
Suggestions for appropriate agents to include in routine antimicrobial susceptibility testing These suggestions are intended to indicate minimum sets of agents to test routinely in a diagnostic laboratory
More informationMicrobiology. Multi-Drug-Resistant bacteria / MDR: laboratory diagnostics and prevention. Antimicrobial resistance / MDR:
Microbiology Multi-Drug-Resistant bacteria / MDR: laboratory diagnostics and prevention June 2017 MeshHp (VS) Medical Care Center Dr. Eberhard & Partner Dortmund (ÜBAG) www.labmed.de MVZ Dr. Eberhard &
More informationCONTAGIOUS COMMENTS Department of Epidemiology
VOLUME XXXII NUMBER 6 September 2017 CONTAGIOUS COMMENTS Department of Epidemiology Bugs and Drugs Elaine Dowell SM MLS (ASCP), Stacey Hamilton MT SM (ASCP), Samuel Dominguez MD PhD, Sarah Parker MD, and
More informationANTIMICROBIAL RESISTANCE SURVEILLANCE FROM SENTINEL PUBLIC HOSPITALS, SOUTH AFRICA, 2014
ANTIMICROBIAL RESISTANCE SURVEILLANCE FROM SENTINEL PUBLIC HOSPITALS, SOUTH AFRICA, 2014 Olga Perovic, 1,2 Verushka Chetty 1 & Samantha Iyaloo 1 1 National Institute for Communicable Diseases, NHLS 2 Department
More informationUCSF guideline for management of suspected hospital-acquired or ventilatoracquired pneumonia in adult patients
Background/methods: UCSF guideline for management of suspected hospital-acquired or ventilatoracquired pneumonia in adult patients This guideline establishes evidence-based consensus standards for management
More informationEUCAST recommended strains for internal quality control
EUCAST recommended strains for internal quality control Escherichia coli Pseudomonas aeruginosa Staphylococcus aureus Enterococcus faecalis Streptococcus pneumoniae Haemophilus influenzae ATCC 59 ATCC
More informationHospital-acquired pneumonia (HAP) is the second
Guidelines and Critical Pathways for Severe Hospital-Acquired Pneumonia* Stanley Fiel, MD, FCCP Hospital-acquired pneumonia (HAP) is associated with high morbidity and mortality. Early, appropriate, and
More informationDetection and Quantitation of the Etiologic Agents of Ventilator Associated Pneumonia in Endotracheal Tube Aspirates From Patients in Iran
Letter to the Editor Detection and Quantitation of the Etiologic Agents of Ventilator Associated Pneumonia in Endotracheal Tube Aspirates From Patients in Iran Mohammad Rahbar, PhD; Massoud Hajia, PhD
More informationTreatment Guidelines and Outcomes of Hospital- Acquired and Ventilator-Associated Pneumonia
SUPPLEMENT ARTICLE Treatment Guidelines and Outcomes of Hospital- Acquired and Ventilator-Associated Pneumonia Antoni Torres, Miquel Ferrer, and Joan Ramón Badia Pneumology Department, Clinic Institute
More informationWhat s next in the antibiotic pipeline?
What s next in the antibiotic pipeline? Jennifer Tieu, Pharm.D., BCPS Clinical Pearls OSHP Spring Meeting Mercy Hospital April 13, 2018 Objective 2 Describe the drug class and mechanism of action of antibiotics
More informationCipro for gram positive cocci in urine
Buscar... Cipro for gram positive cocci in urine 20-6-2017 Pneumonia can be generally defined as an infection of the lung parenchyma, in which consolidation of the affected part and a filling of the alveolar
More informationAntimicrobial Stewardship Strategy: Antibiograms
Antimicrobial Stewardship Strategy: Antibiograms A summary of the cumulative susceptibility of bacterial isolates to formulary antibiotics in a given institution or region. Its main functions are to guide
More informationFlorida Health Care Association District 2 January 13, 2015 A.C. Burke, MA, CIC
Florida Health Care Association District 2 January 13, 2015 A.C. Burke, MA, CIC 11/20/2014 1 To describe carbapenem-resistant Enterobacteriaceae. To identify laboratory detection standards for carbapenem-resistant
More informationUpdate on Resistance and Epidemiology of Nosocomial Respiratory Pathogens in Asia. Po-Ren Hsueh. National Taiwan University Hospital
Update on Resistance and Epidemiology of Nosocomial Respiratory Pathogens in Asia Po-Ren Hsueh National Taiwan University Hospital Ventilator-associated Pneumonia Microbiological Report Sputum from a
More informationAppropriate Management of Common Pediatric Infections. Blaise L. Congeni M.D. Akron Children s Hospital Division of Pediatric Infectious Diseases
Appropriate Management of Common Pediatric Infections Blaise L. Congeni M.D. Akron Children s Hospital Division of Pediatric Infectious Diseases It s all about the microorganism The common pathogens Viruses
More informationCommunity Acquired Pneumonia. Epidemiology: Acute Lower Respiratory Tract Infections. Community Acquired Pneumonia (CAP) Outline
Community Acquired Pneumonia (CAP) Outline Lisa G. Winston, MD University of California, San Francisco Zuckerberg San Francisco General Epidemiology Diagnosis Microbiology Risk stratification Treatment
More informationSafe Patient Care Keeping our Residents Safe Use Standard Precautions for ALL Residents at ALL times
Safe Patient Care Keeping our Residents Safe 2016 Use Standard Precautions for ALL Residents at ALL times #safepatientcare Do bugs need drugs? Dr Deirdre O Brien Consultant Microbiologist Mercy University
More informationIDSA GUIDELINES COMMUNITY ACQUIRED PNEUMONIA
page 1 / 5 page 2 / 5 idsa guidelines community acquired pdf IDSA/ATS Guidelines for CAP in Adults CID 2007:44 (Suppl 2) S29 such as blood and sputum cultures. Conversely, these cultures may have a major
More informationInfectious Disease 101: Helping the Consultant Pharmacist with Stewardship Principles
Infectious Disease 101: Helping the Consultant Pharmacist with Stewardship Principles Conflicts of Interest None at this time May be discussing off-label indications KALIN M. CLIFFORD, PHARM.D., BCPS,
More informationAntibiotics in the Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease
Antibiotics in the Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease Sung Kyu Kim, M.D.Young Sam Kim, M.D. Department of Internal Medicine Yonsei University College of Medicine,
More informationComparative Assessment of b-lactamases Produced by Multidrug Resistant Bacteria
Comparative Assessment of b-lactamases Produced by Multidrug Resistant Bacteria Juhee Ahn Department of Medical Biomaterials Engineering Kangwon National University October 23, 27 Antibiotic Development
More informationEducating Clinical and Public Health Laboratories About Antimicrobial Resistance Challenges
Educating Clinical and Public Health Laboratories About Antimicrobial Resistance Challenges Janet Hindler, MCLS MT(ASCP) UCLA Medical Center jhindler@ucla.edu also working as a consultant with the Association
More informationChildrens Hospital Antibiogram for 2012 (Based on data from 2011)
Childrens Hospital Antibiogram for 2012 (Based on data from 2011) Prepared by: Department of Clinical Microbiology, Health Sciences Centre For further information contact: Andrew Walkty, MD, FRCPC Medical
More informationOCTOBER 7-10 PHILADELPHIA, PENNSYLVANIA
OMED 17 OCTOBER 7-10 PHILADELPHIA, PENNSYLVANIA 29.5 Category 1-A CME credits anticipated ACOFP / AOA s 122 nd Annual Osteopathic Medical Conference & Exposition Joint Session with ACOFP and Cleveland
More informationCompliance of manufacturers of AST materials and devices with EUCAST guidelines
Compliance of manufacturers of AST materials and devices with EUCAST guidelines Data are based on questionnaires to manufacturers of materials and devices for antimicrobial susceptibility testing. The
More informationWhat s new in EUCAST methods?
What s new in EUCAST methods? Derek Brown EUCAST Scientific Secretary Interactive question 1 MIC determination MH-F broth for broth microdilution testing of fastidious microorganisms Gradient MIC tests
More informationThe Basics: Using CLSI Antimicrobial Susceptibility Testing Standards
The Basics: Using CLSI Antimicrobial Susceptibility Testing Standards Janet A. Hindler, MCLS, MT(ASCP) UCLA Health System Los Angeles, California, USA jhindler@ucla.edu 1 Learning Objectives Describe information
More informationETX0282, a Novel Oral Agent Against Multidrug-Resistant Enterobacteriaceae
ETX0282, a Novel Oral Agent Against Multidrug-Resistant Enterobacteriaceae Thomas Durand-Réville 02 June 2017 - ASM Microbe 2017 (Session #113) Disclosures Thomas Durand-Réville: Full-time Employee; Self;
More informationQUICK REFERENCE. Pseudomonas aeruginosa. (Pseudomonas sp. Xantomonas maltophilia, Acinetobacter sp. & Flavomonas sp.)
Pseudomonas aeruginosa (Pseudomonas sp. Xantomonas maltophilia, Acinetobacter sp. & Flavomonas sp.) Description: Greenish gray colonies with some beta-hemolysis around each colony on blood agar (BAP),
More informationESCMID Online Lecture Library. by author
Expert rules in susceptibility testing EUCAST-ESGARS-EPASG Educational Workshop Linz, 16 19 September, 2014 Dr. Rafael Cantón Hospital Universitario Ramón y Cajal SERVICIO DE MICROBIOLOGÍA Y PARASITOLOGÍA
More informationFinnzymes Oy. PathoProof Mastitis PCR Assay. Real time PCR based mastitis testing in milk monitoring programs
PathoProof TM Mastitis PCR Assay Mikko Koskinen, Ph.D. Director, Diagnostics, Finnzymes Oy Real time PCR based mastitis testing in milk monitoring programs PathoProof Mastitis PCR Assay Comparison of the
More informationa. 379 laboratories provided quantitative results, e.g (DD method) to 35.4% (MIC method) of all participants; see Table 2.
AND QUANTITATIVE PRECISION (SAMPLE UR-01, 2017) Background and Plan of Analysis Sample UR-01 (2017) was sent to API participants as a simulated urine culture for recognition of a significant pathogen colony
More informationRoutine internal quality control as recommended by EUCAST Version 3.1, valid from
Routine internal quality control as recommended by EUCAST Version.1, valid from 01-01-01 Escherichia coli Pseudomonas aeruginosa Staphylococcus aureus Enterococcus faecalis Streptococcus pneumoniae Haemophilus
More informationIn Vitro Antimicrobial Activity of CP-99,219, a Novel Azabicyclo-Naphthyridone
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Feb. 993, p. 39-353 0066-0/93/0039-05$0.00/0 Copyright 993, American Society for Microbiology Vol. 37, No. In Vitro Antimicrobial Activity of, a Novel Azabicyclo-Naphthyridone
More informationMulti-drug resistant microorganisms
Multi-drug resistant microorganisms Arzu TOPELI Director of MICU Hacettepe University Faculty of Medicine, Ankara-Turkey Council Member of WFSICCM Deaths in the US declined by 220 per 100,000 with the
More informationTreatment of Respiratory Tract Infections Prof. Mohammad Alhumayyd Dr. Aliah Alshanwani
Treatment of Respiratory Tract Infections Prof. Mohammad Alhumayyd Dr. Aliah Alshanwani 30-1-2018 1 Objectives of the lecture At the end of lecture, the students should be able to understand the following:
More informationFIS Resistance Surveillance: The UK Landscape. Alasdair MacGowan Chair BSAC Working Party on Antimicrobial Resistance Surveillance
FIS 2013 Resistance Surveillance: The UK Landscape Alasdair MacGowan Chair BSAC Working Party on Antimicrobial Resistance Surveillance A statement of the obvious Good quality surveillance data on resistant
More informationPrinciples of Infectious Disease. Dr. Ezra Levy CSUHS PA Program
Principles of Infectious Disease Dr. Ezra Levy CSUHS PA Program I. Microbiology (1) morphology (e.g., cocci, bacilli) (2) growth characteristics (e.g., aerobic vs anaerobic) (3) other qualities (e.g.,
More information